EAM
CPRX icon

Exome Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Exome Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-105,500
Closed -$1.77M – 57
2023
Q4 		$1.77M Buy
+105,500
New +$1.44M 1.75% 25

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Exome Asset Management's CPRX Position: Q1 2024 in Review

Exome Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 105,500 shares — an estimated $1.77M sold.

Exome Asset Management first reported a position in CPRX in Q4 2023 and held it in 1 quarter. The position peaked at $1.77M in Q4 2023. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Exome Asset Management reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Exome Asset Management sold 105,500 Catalyst Pharmaceutical shares in Q1 2024, an estimated $1.77M.
  • Exome Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 1 quarter.
  • Exome Asset Management's Catalyst Pharmaceutical position peaked at $1.77M in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.